A Blood-Brain Barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: A novel dual mechanism of mannitol for the treatment of Parkinson Disease (PD)

Journal of Biological Chemistry

Volumn 288, Issue 24, 2013, Pages 17579-17588

  Shaltiel Karyo, Ronit ^a   Frenkel Pinter, Moran ^a   Rockenstein, Edward ^b   Patrick, Christina ^b   Levy Sakin, Michal ^a   Schiller, Abigail ^a   Egoz Matia, Nirit ^a   Masliah, Eliezer ^b   Segal, Daniel ^a   Gazit, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATION INHIBITORS; AGGREGATION PROCESS; BLOOD-BRAIN BARRIER; DIFFERENT STRUCTURE; HIGH MOLECULAR WEIGHT; NEUROPROTECTIVE EFFECTS; SECONDARY STRUCTURES; THERAPEUTIC AGENTS;

AGGLOMERATION; BLOOD; BRAIN; DISEASE CONTROL; DISEASES; OLIGOMERS; POLYOLS;

DRUG PRODUCTS;

ALPHA SYNUCLEIN; HEAT SHOCK PROTEIN 70; MANNITOL; OLIGOMER; TETRAMER;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BIOACCUMULATION; BLOOD BRAIN BARRIER; CIRCULAR DICHROISM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DROSOPHILA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MOUSE; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SECONDARY STRUCTURE; UPREGULATION;

ALPHA-SYNUCLEIN; AMYLOID; BIOPHYSICS; BLOOD-BRAIN BARRIER; BRAIN; CHEMICAL CHAPERONE; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; AMYLOID; ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; DROSOPHILA; FEMALE; FLUORESCENT DYES; HIPPOCAMPUS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LOCOMOTION; MALE; MANNITOL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; NEOCORTEX; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; THIAZOLES;

MUS; MUS MUSCULUS;

EID: 84879052027     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.434787     Document Type: Article

References (41)

1. Begley, D. J. (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104, 29-45
2. Liu, X., and Chen, C. (2005) Strategies to optimize brain penetration in drug discovery. Curr. Opin. Drug Discov. Devel. 8, 505-512 (Pubitemid 40917412)
3. Gabathuler, R. (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48-57
4. de Boer, A. G., and Gaillard, P. J. (2007) Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355
5. Pan, G. Y., Liu, X. D., and Liu, G. Q. (2000) Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats. Acta Pharmacol. Sin. 21, 613-616
6. Malek, A. M., Goss, G. G., Jiang, L., Izumo, S., and Alper, S. L. (1998) Mannitol at clinical concentrations activates multiple signaling pathways and induces apoptosis in endothelial cells. Stroke 29, 2631-2640 (Pubitemid 28544016)
7. Suzuki, J., Imaizumi, S., Kayama, T., and Yoshimoto, T. (1985) Chemiluminescence in hypoxic brain-the second report: cerebral protective effect of mannitol, vitamin E, and glucocorticoid. Stroke 16, 695-700 (Pubitemid 15007248)
8. Ruijter, G. J., Bax, M., Patel, H., Flitter, S. J., van de Vondervoort, P. J., de Vries, R. P., vanKuyk, P. A., and Visser, J. (2003) Mannitol is required for stress tolerance in Aspergillus niger conidiospores. Eukaryot Cell 2, 690-698 (Pubitemid 36996715)
9. Lu, D., Liu, Z., and Wu, J. (2006) Structural transitions of confined model proteins: molecular dynamics simulation and experimental validation. Biophys. J. 90, 3224-3238
10. Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., and Rocca, W. A. (2002) Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 55, 25-31 (Pubitemid 34044099)
11. Forno, L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272
12. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840
13. Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., and Stefanis, L. (2011) Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10, 1015-1025
14. Hashimoto, M., Kawahara, K., Bar-On, P., Rockenstein, E., Crews, L., and Masliah, E. (2004) The role of α-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J. Mol. Neurosci. 24, 343-352 (Pubitemid 41389374)
15. Tofaris, G. K., and Spillantini, M. G. (2005) α-Synuclein dysfunction in Lewy body diseases. Mov. Disord. 20, Suppl. 12, S37-S44 (Pubitemid 41419553)
16. Sipe, J. D. (1992) Amyloidosis. Annu. Rev. Biochem. 61, 947-975
17. Wetzel, R. (1994) Mutations and off-pathway aggregation of proteins. Trends Biotechnol. 12, 193-198
18. Leong, S. L., Cappai, R., Barnham, K. J., and Pham, C. L. (2009) Modulation of α-synuclein aggregation by dopamine: a review. Neurochem. Res. 34, 1838-1846
19. Holthauzen, L. M., and Bolen, D. W. (2007) Mixed osmolytes: the degree to which one osmolyte affects the protein stabilizing ability of another. Protein Sci. 16, 293-298 (Pubitemid 46155777)
20. Perlmutter, D. H. (2002) Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr. Res. 52, 832-836
21. Rajan, R. S., Tsumoto, K., Tokunaga, M., Tokunaga, H., Kita, Y., and Arakawa, T. (2011) Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases. Curr. Med. Chem. 18, 1-15
22. Chaudhuri, T. K., and Paul, S. (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 273, 1331-1349 (Pubitemid 44029101)
23. Samiotakis, A., Wittung-Stafshede, P., and Cheung, M. S. (2009) Folding, stability and shape of proteins in crowded environments: experimental and computational approaches. Int. J. Mol. Sci. 10, 572-588
24. Munishkina, L. A., Ahmad, A., Fink, A. L., and Uversky, V. N. (2008) Guiding protein aggregation with macromolecular crowding. Biochemistry 47, 8993-9006
25. Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., and Masliah, E. (2002) Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568-578 (Pubitemid 34575622)
26. Volles, M. J., and Lansbury, P. T., Jr. (2007) Relationships between the sequence of α-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J. Mol. Biol. 366, 1510-1522 (Pubitemid 46215614)
27. Tsigelny, I. F., Bar-On, P., Sharikov, Y., Crews, L., Hashimoto, M., Miller, M. A., Keller, S. H., Platoshyn, O., Yuan, J. X., and Masliah, E. (2007) Dynamics of α-synuclein aggregation and inhibition of pore-like oligomer development by β-synuclein. FEBS J. 274, 1862-1877 (Pubitemid 46426920)
28. Fleming, S. M., Salcedo, J., Hutson, C. B., Rockenstein, E., Masliah, E., Levine, M. S., and Chesselet, M. F. (2006) Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype α-synuclein. Neuroscience 142, 1245-1253 (Pubitemid 44636058)
29. Fleming, S. M., Salcedo, J., Fernagut, P. O., Rockenstein, E., Masliah, E., Levine, M. S., and Chesselet, M. F. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein. J. Neurosci. 24, 9434-9440 (Pubitemid 39426179)
30. Shults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., and Masliah, E. (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 25, 10689-10699 (Pubitemid 41681917)
31. Crowther, D. C., Kinghorn, K. J., Miranda, E., Page, R., Curry, J. A., Duthie, F. A., Gubb, D. C., and Lomas, D. A. (2005) Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 132, 123-135 (Pubitemid 40380720)
32. Frydman-Marom, A., Levin, A., Farfara, D., Benromano, T., Scherzer-Attali, R., Peled, S., Vassar, R., Segal, D., Gazit, E., Frenkel, D., and Ovadia, M. (2011) Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One 6, e16564
33. Scherzer-Attali, R., Pellarin, R., Convertino, M., Frydman-Marom, A., Egoz-Matia, N., Peled, S., Levy-Sakin, M., Shalev, D. E., Caflisch, A., Gazit, E., and Segal, D. (2010) Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One 5, e11101
34. Shaltiel-Karyo, R., Frenkel-Pinter, M., Egoz-Matia, N., Frydman-Marom, A., Shalev, D. E., Segal, D., and Gazit, E. (2010) Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One 5, e13863
35. Feany, M. B., and Bender, W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398 (Pubitemid 30164341)
36. Richmon, J. D., Fukuda, K., Sharp, F. R., and Noble, L. J. (1995) Induction of HSP-70 after hyperosmotic opening of the blood-brain barrier in the rat. Neurosci. Lett. 202, 1-4 (Pubitemid 26011550)
37. Cookson, M. R. (2009) α-Synuclein and neuronal cell death. Mol. Neurodegener. 4, 9
38. Butler, T. (2007) Complexities in the association of human blood brain barrier disruption with seizures: importance of patient population and method of disruption. Brain 130, e77
39. Welch, W. J. (2004) Role of quality control pathways in human diseases involving protein misfolding. Semin. Cell Dev. Biol. 15, 31-38
40. Barral, J. M., Broadley, S. A., Schaffar, G., and Hartl, F. U. (2004) Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 15, 17-29 (Pubitemid 38177364)
41. 2+ exchange blocker on blood-brain barrier opening. Biochem. Biophys. Res. Commun. 291, 669-674